916263-24-6

Usage

Function

b-amyloid (Aβ) peptide aggregation inhibitor
The compound is capable of inhibiting the aggregation of Aβ peptides, which are implicated in neurodegenerative diseases like Alzheimer's.

Application

Pharmaceutical research for treating neurodegenerative diseases
It is used in the development of potential treatments for Alzheimer's disease and other conditions involving neurodegeneration.

Status

Under investigation as a potential therapeutic agent for Alzheimer's disease
The compound is currently being studied for its efficacy and safety in treating Alzheimer's disease.

Chemical structure

Pyrrolidine ring, carboxylic acid group, and various aromatic and aliphatic side chains
The compound's structure features a pyrrolidine ring, a carboxylic acid group, and multiple side chains, which contribute to its versatility and potential value in medicinal chemistry research.

Upstream product

• 4897-68-1 2-iodo-4-methoxybromobenzene 
• 766-85-8 3-methoxy-1-iodobenzene 
• 916263-22-4 2-bromo-3',4'-methylenedioxy-5-methoxybiphenyl 
• 916263-17-7 1,1-dimethylethyl (2R)-2-(2-propyn-1-yl)-1-pyrrolidinecarboxylate 
• 916263-23-5 2-iodo-3',4'-methylenedioxy-5-methoxybiphenyl 

Relevant academic research and scientific papers

Total syntheses of the tylophora alkaloids cryptopleurine, (-)-antofine, (-)-tylophorine, and (-)-ficuseptine C

A concise, efficient and modular approach to the tylophora alkaloids is described, a family of potent cytotoxic agents that are equally effective against drug sensitive and multidrug resistant cancer cell lines. The advantages of the chosen route are illustrated by the total syntheses of the phenanthroquinolizidine cryptopleurine (1) and the phenanthroindolizidines (-)-antofine (2), (-)-tylophorine (3), and their only recently isolated congener (-)-ficuseptine C (4). The key steps consist in a Suzuki cross-coupling between a (commercial) boronic acid and a simple aryl-l,2-dihalide followed by elaboration of the resulting products into the corresponding 2-alkynyl-biphenyl derivatives 27, 33, 41 and 46. The latter undergo PtCl2-catalyzed cycloisomerizations with formation of the functionalized phenanthrenes 28, 34, 42 and 47, which were transformed into the targeted alkaloids by a deprotection/Pictet-Spengler annulation tandem. Due to the flexibility and robust character of this approach, it might enable a systematic exploration of the pharmacological profile of this promising class of bioactive natural products.